Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Show full item record



Permalink

http://hdl.handle.net/10138/338077

Citation

Yoo , S-J , Chang , S-A , Sohn , T S , Kwon , H-S , Lee , J M , Moon , S , Proot , P , Paldanius , P M & Yoon , K H 2021 , ' Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus ' , Diabetes & metabolism journal , vol. 45 , no. 6 , pp. 954-959 . https://doi.org/10.4093/dmj.2020.0173

Title: Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Author: Yoo, Soon-Jib; Chang, Sang-Ah; Sohn, Tae Seo; Kwon, Hyuk-Sang; Lee, Jong Min; Moon, Sungdae; Proot, Pieter; Paldanius, Päivi M.; Yoon, Kun Ho
Contributor organization: HUS Children and Adolescents
Children's Hospital
Clinicum
CAMM - Research Program for Clinical and Molecular Metabolism
Date: 2021-11
Language: eng
Number of pages: 6
Belongs to series: Diabetes & metabolism journal
ISSN: 2233-6079
DOI: https://doi.org/10.4093/dmj.2020.0173
URI: http://hdl.handle.net/10138/338077
Abstract: We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c]>= 7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.
Subject: Diabetes mellitus
type 2
Drug therapy
combination
Glycated hemoglobin A
Korea
Metformin
Vildagliptin
GLUCOSE
ASIA
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
dmj_2020_0173.pdf 144.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record